Lund/Mannheim, 12. Februar 2019 – Wie Camurus (NASDAQ STO: CAMX) heute bekannt gab, ist das wöchentlich oder monatlich anzuwendende Buvidal® (Buprenorphin-Depotlösung zur subkutanen Injektion) ab sofort in Deutschland verfügbar. Buvidal® ist das ers…

No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study. Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci…

Buprenorphine for the treatment of posttraumatic stress disorder. Lake EP, Mitchell BG, Shorter DI, Kosten T, Domingo CB, Walder AM. Am J Addict. 2019 Jan 21. doi: 10.1111/ajad.12860.  Abstract https://www.ncbi.nlm.nih.gov/pubmed/30664299…

Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression. Lin C, Karim HT, Pecina M, Aizenstein HJ, Lenze EJ, Blumberger DM, Mulsant BH, Kharasch ED, Reynol…

Use of Generally Recognized as Safe or Dietary Compounds to Inhibit Buprenorphine Metabolism: Potential to Improve Buprenorphine Oral Bioavailability. Maharao N, Venitz J, Gerk PM. Biopharm Drug Dispos. 2018 Dec 5. doi: 10.1002/bdd.2166.  Ab…

Care-by-parent model as a tool for reduction in neonatal opioid withdrawal syndrome in neonates exposed to buprenorphine maintenance therapy in-utero. Lawlor ML, Shook L, McQuerry K, Srinivasan A, Johnson QB, Chavan NR, Critchfield AS. J Matern Fe…